

89. Meyers MO, Yeh JJ, Frank J, et al. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. *Ann Surg Oncol*. 2009;16:941-947.
90. Berger AC, Ollila DW, Christopher A, et al. Patient symptoms are the most frequent indicators of recurrence in patients with American Joint Committee on Cancer stage II melanoma. *J Am Coll Surg*. 2017;224:652-659.
91. Podlipnik S, Carrera C, Sanchez M, et al. Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: a prospective cohort study. *J Am Acad Dermatol*. 2016;75:516-524.
92. Xing Y, Cromwell KD, Cormier JN. Review of diagnostic imaging modalities for the surveillance of melanoma patients. *Dermatol Res Pract*. 2012;2012:941921.

Answers to CME examination

Identification No. JB0119

January 2019 issue of the Journal of the American Academy of Dermatology.

Klapperich ME, Bowen GM, Grossman D. *J Am Acad Dermatol* 2019;80:15-25.

1.b
2.c

3.e